In summary, combining EGFR-tyrosine kinase inhibitors with α-PD-1/PD-L1 therapy has the potential to maximize the effectiveness of immunotherapy in individuals diagnosed with EGFR-mutated cancers [21]. The gene discussed is EGFR; the disease is cancer.